Fractyl Health (NASDAQ:GUTS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Fractyl Health (NASDAQ:GUTS) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock.

A number of other analysts have also recently commented on the stock. LADENBURG THALM/SH SH began coverage on shares of Fractyl Health in a research note on Thursday, August 28th. They set a “buy” rating and a $3.60 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a report on Wednesday, October 8th. Finally, Canaccord Genuity Group boosted their price objective on Fractyl Health from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 21st. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Fractyl Health currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Fractyl Health Trading Up 17.9%

Shares of GUTS stock opened at $1.84 on Tuesday. Fractyl Health has a 1-year low of $0.83 and a 1-year high of $3.03. The company has a market cap of $252.15 million, a price-to-earnings ratio of -0.80 and a beta of 1.96. The company has a debt-to-equity ratio of 4.61, a current ratio of 4.27 and a quick ratio of 4.27. The stock has a 50 day simple moving average of $1.33 and a 200-day simple moving average of $1.45.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, equities research analysts expect that Fractyl Health will post -1.61 EPS for the current fiscal year.

Institutional Trading of Fractyl Health

Hedge funds have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd acquired a new position in shares of Fractyl Health during the 2nd quarter worth approximately $26,000. Jane Street Group LLC purchased a new position in Fractyl Health during the second quarter worth approximately $31,000. Chicago Partners Investment Group LLC acquired a new position in Fractyl Health during the first quarter worth $37,000. HighTower Advisors LLC boosted its stake in Fractyl Health by 57.9% during the first quarter. HighTower Advisors LLC now owns 40,921 shares of the company’s stock worth $49,000 after buying an additional 15,000 shares during the last quarter. Finally, Scientech Research LLC purchased a new stake in Fractyl Health in the 3rd quarter valued at $49,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.